Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.58 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422 | 0.90 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL12002388 | 0.89 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15043618 | 0.87 | SLC6A4 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL9399121 | 0.85 | CNR2 (0.57) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL15043625 | 0.84 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12002389 | 0.83 | SLC6A3 (0.59) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL28168403 | 0.83 | CNR2 (0.46) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL5682331 | 0.83 | CNR2 (0.52) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL15568275 | 0.82 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2CNR2CNR1 | |
| SCHEMBL15042375 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2698/4885SLC6A3 2766/4885SLC6A2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.